DexCom, Inc. DXCM announced that the FDA has approved its G6 Pro Continuous Glucose Monitoring (“CGM”) System for use on patients (aged two years and up). This further fortifies DexCom’s foothold in ...

SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM) announced today the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for ...

Dexcom has announced that the US Food and Drug Administration (FDA) has approved its G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients aged 2 ...

This morning the Dexcom G6 Pro Continuous Glucose Monitoring System got the greenlight from the FDA. The latest technology can gather real-time glucose data over a period of 10 days and has the ...

Dexcom is continuing to build upon its continuous glucose monitoring (CGM) story with a new nod from FDA. The San Diego-based company received clearance from the federal agency for the Dexcom G6 Pro ...

When it comes to the diabetes space, Dexcom is one of the heavy hitters. Its work in the continuous glucose monitoring space has put it on the map. In 2018, its Dexcom G6, an integrated continuous ...

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Please provide your email address to receive an email when new articles are posted on . The FDA on Tuesday approved the use of a professional continuous glucose monitoring system from Dexcom, ...

Dexcom provides more choice to users by launching Spanish-language capabilities for its mobile app for the best-selling real-time CGM in the world Spanish-speaking patients can opt to use the Dexcom ...